A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea

Recruiting now

Conditions studied: Colorectal Cancer

In brief

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.

Key facts

Study ID

NCT07035886

Run by

Takeda

People needed

600

Starts

2025-09-29

Expected to finish

2031-03-01

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than or equal to (>=)18 years.
• Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
• Participant voluntarily consent to participate in the study.

You may not qualify if…

• Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
• Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
• Pregnant or breastfeeding women.

Where it is running

• Yonsei University Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.